title: Growth inhibitory effect of bestatin on choriocarcinoma cell lines in vitro.
abstract: Bestatin, one of the biological response modifiers (BRMs), is an inhibitor of aminopeptidase B (AP-B), leucine aminopeptidase (LAP) and aminopeptidase M (AP-M). In this report, we investigated the direct effect of bestatin on the growth of cancer cells in vitro using established four choriocarcinoma cell lines. In vitro chemosensitivity was evaluated by the succinate dehydrogenase inhibition (SDI) test. Bestatin showed the growth-inhibitory effect on all the choriocarcinoma cell lines dose-dependently, especially on NaUCC-4 cells. Both an isomer of bestatin with no inhibitory activity against aminopeptidases, (2R, 3S)-AHPA-(R)-Leu, and another isomer with stronger inhibitory activity against AP-B than bestatin, (2S, 3S)-AHPA-(R)-Leu, did not show growth inhibition on NaUCC-4 cells. So it is suggested that one of the possible mechanisms responsible for the direct action of bestatin on the choriocarcinoma cells may be related to the inhibition of activity of LAP or AP-M rather than that of AP-B. Furthermore, cytotoxicity of actinomycin D on the choriocarcinoma cells was significantly enhanced by combination with bestatin. These results suggest that bestatin has not only an indirect host-mediated anti-tumor activity, but also a direct growth-inhibitory effect on some kinds of cancer cell lines.
authors.affiliation: Department of Obstetrics and Gynecology, Nagoya University School of Medicine, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Ino
authors.forename: S
authors.initials: S
authors.lastname: Goto
authors.forename: A
authors.initials: A
authors.lastname: Kosaki
authors.forename: S
authors.initials: S
authors.lastname: Nomura
authors.forename: E
authors.initials: E
authors.lastname: Asada
authors.forename: T
authors.initials: T
authors.lastname: Misawa
authors.forename: Y
authors.initials: Y
authors.lastname: Furuhashi
authors.forename: S
authors.initials: S
authors.lastname: Mizutani
authors.forename: Y
authors.initials: Y
authors.lastname: Tomoda
mesh_terms: D000626:Aminopeptidases / Q000037:antagonists & inhibitors; D002822:Choriocarcinoma / Q000473:pathology*; D003609:Dactinomycin / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007930:Leucine / Q000031:analogs & derivatives* / Q000494:pharmacology; D011247:Pregnancy; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D013385:Succinate Dehydrogenase / Q000037:antagonists & inhibitors; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014594:Uterine Neoplasms / Q000473:pathology*
chemical_list: D003609:Dactinomycin; D013385:Succinate Dehydrogenase; D000626:Aminopeptidases; D007930:Leucine; C012211:ubenimex